Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19611471 | 1.00 | MEN1 (0.59) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL12755039 | 0.92 | MEN1 (0.58) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL27515193 | 0.92 | MEN1 (0.58) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL4670568 | 0.88 | MEN1 (0.56) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL6823852 | 0.87 | MEN1 (0.69) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL5079004 | 0.87 | MEN1 (0.64) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL2032033 | 0.87 | MEN1 (0.69) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL7194401 | 0.84 | MEN1 (0.60) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL567299 | 0.84 | MAOA (0.47) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL14871948 | 0.84 | MEN1 (0.59) | MEN1KMT2AGAATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSTY | 2020-11-19 | — | — | US | disclosed |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | MEN1 844/4885KMT2A 3647/4885GAA 402/4885 |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | MEN1 844/4885KMT2A 3647/4885GAA 402/4885 |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | MEN1 1001/4885KMT2A 3946/4885GAA 605/4885 |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | MEN1 844/4885KMT2A 3647/4885GAA 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.